Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy.

A C Wolff1

  • 1The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. awolff@jhmi.edu

Current Opinion in Oncology
|November 5, 1999
PubMed
Summary
This summary is machine-generated.

Recent advancements in systemic breast cancer therapy include anthracycline benefits over CMF, tamoxifen for noninvasive disease, and new data on HER-2 targeted treatments and taxanes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

ESMO open·2026
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

HER2DX genomic test in early-stage HER2-positive breast cancer.

ESMO open·2024
Same author

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Medical treatment of breast cancer

Background:

  • Systemic therapy for breast cancer is continually evolving.
  • Recent data refine understanding of adjuvant and primary treatment options.

Purpose of the Study:

  • To review recent advances in systemic therapy for breast cancer.
  • To highlight new findings on chemotherapy, hormonal therapy, and targeted agents.

Main Methods:

  • Review of the third Oxford Overview on adjuvant systemic therapy.
  • Analysis of new data on various systemic treatments including chemotherapy regimens, tamoxifen, biphosphonates, and anti-HER-2 therapies.
  • Evaluation of emerging roles for taxanes and high-dose chemotherapy.

Main Results:

  • Anthracycline regimens show a small advantage over cyclophosphamide, methotrexate, and 5-fluorouracil (CMF).

Related Experiment Videos

  • Primary chemotherapy enhances breast conservation rates without improving survival.
  • Tamoxifen demonstrates benefits for noninvasive breast cancer.
  • New data support the use of biphosphonates, ovarian ablation, and anti-estrogens.
  • Anti-HER-2 antibody and HER-2 expression are significant factors.
  • Taxanes show expanding roles in early and advanced breast cancer.

    • Conclusions:

    • Systemic therapy for breast cancer has seen significant recent progress.
    • Advances include refined chemotherapy regimens, expanded roles for hormonal and targeted therapies, and improved breast conservation strategies.